source: Archives of Endocrinology and Metabolism
authors: Santarosa VA, Orlandi DM, Fiorin LB, Kasamatsu TS, Furuzawa GK1, Kunii IS, Padovani RP, Marone MM, Castiglioni ML, Vieira JG, Maciel RM, Dias-da-Silva MR, Martins JR summary/abstract:
Consuming a low-iodine diet (LID) is a widely accepted practice before administering radioiodine (131I) to evaluate and to treat thyroid disease. Although this procedure is well established for the management of patients with differentiated thyroid cancer, its use in patients with benign disease is unclear. So, we aimed to evaluate the influence of a LID on the outcome in patients with Graves’ disease (GD) treated with 131I.
Subjects and Methods:
We evaluated 67 patients with GD who were divided into 2 groups: one group (n = 31) consumed a LID for 1-2 weeks, and the second group (n = 36) was instructed to maintain a regular diet (RD).
The LID group experienced a 23% decrease in urinary iodine after 1 week on the diet and a significant 42% decrease after 2 weeks on the diet. The majority (53%) of the patients in the LID group had urinary iodine levels that were consistent with deficient iodine intake. However, there was no difference in the rate of hyperthyroidism’s cure between the LID and the RD groups 6 months after 131I therapy. Furthermore, the therapeutic efficacy did not differ in patients with varying degrees of sufficient iodine intake (corresponding urinary iodine levels: < 10 μg/dL is deficient; 10-29.9 μg/dL is sufficient; and > 30 μg/dL is excessive).
In the present study, we demonstrated that although a LID decreased urinary iodine levels, those levels corresponding with sufficient or a mild excess in iodine intake did not compromise the therapeutic efficacy of 131I for the treatment of GD.
Universidade Federal de São Paulo, Brazil; Irmandade Santa Casa de Misericórdia de São Paulo, Brazil; Unifesp, Brazil DOI:
10.1590/2359-3997000000082 full text source